TORC1/2抑制剂TAK228使非典型畸胎样/横纹肌样肿瘤对顺铂诱导的细胞毒性敏感
研究探讨TAK228单药及联合顺铂对非典型畸胎样/横纹肌样肿瘤(AT/RT)的疗效。在18例原发AT/RT肿瘤中,pS6和pAKT(Ser473)高表达率分别为21%和87%;TAK228可抑制细胞生长、诱导凋亡,并使原位异种移植模型的中位生存期近乎翻倍,与顺铂联用协同增效并显著延长生存期。
要点
- 21%和87%的原发AT/RT肿瘤分别高表达pS6和pAKT(Ser473)。
- TAK228单药使原位异种移植模型中位生存期近乎翻倍。
- TAK228联合顺铂协同抑制生长、增强凋亡并显著延长生存期。
核心结论
- TAK228单药在AT/RT中有效,并通过使肿瘤对顺铂诱导的凋亡敏感而与常规化疗协同;结果提示TAK228可能是AT/RT的有效新治疗。
研究设计与样本
- 在18例原发AT/RT肿瘤的组织芯片上用免疫组化检测pS6和pAKT(Ser473)以确定mTOR激活。
- 采用体外生长实验(BrdU和MTS)、死亡实验(western blot检测CC3、c-PARP)及原位异种移植模型生存曲线,评估TAK228单药及联合顺铂的疗效。
主要发现
- 慢病毒短发夹RNA介导的LIN28A敲低导致mTOR激活下降。
- 原发人AT/RT肿瘤中pS6和pAKT(Ser473)高表达率分别为21%和87%。
- TAK228减缓细胞生长、诱导体外凋亡,并使原位异种移植模型的中位生存期近乎翻倍。
- TAK228联合顺铂协同减缓细胞生长并增强顺铂诱导的凋亡;抑制AKT使细胞对顺铂诱导的凋亡敏感,而强制激活AKT则保护细胞。
- 与单药相比,TAK228联合顺铂显著延长原位异种移植模型的生存期。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atypical teratoid/rhabdoid tumors (AT/RTs) are deadly pediatric brain tumors driven by LIN28. Mammalian target of rapamycin (mTOR) is activated in many deadly, drug-resistant cancers and governs important cellular functions such as metabolism and survival. LIN28 regulates mTOR in normal cells. We therefore hypothesized that mTOR is activated downstream of LIN28 in AT/RT, and the brain-penetrating mTOR complex 1 and 2 (mTORC1/2) kinase inhibitor TAK228 would reduce AT/RT tumorigenicity. METHODS: Activation of mTOR in AT/RT was determined by measuring pS6 and pAKT (Ser473) by immunohistochemistry on tissue microarray of 18 primary AT/RT tumors. In vitro growth assays (BrdU and MTS), death assays (CC3, c-PARP by western blot), and survival curves of AT/RT orthotopic xenograft models were used to measure the efficacy of TAK228 alone and in combination with cisplatin. RESULTS: Lentiviral short hairpin RNA-mediated knockdown of LIN28A led to decreased mTOR activation. Primary human AT/RT had high levels of pS6 and pAKT (Ser473) in 21% and 87% of tumors by immunohistochemistry. TAK228 slowed cell growth, induced apoptosis in vitro, and nearly doubled median survival of orthotopic xenograft models of AT/RT. TAK228 combined with cisplatin synergistically slowed cell growth and enhanced cisplatin-induced apoptosis. Suppression of AKT sensitized cells to cisplatin-induced apoptosis and forced activation of AKT protected cells. Combined treatment with TAK228 and cisplatin significantly extended survival of orthotopic xenograft models of AT/RT compared with each drug alone. CONCLUSIONS: TAK228 has efficacy in AT/RT as a single agent and synergizes with conventional chemotherapies by sensitizing tumors to cisplatin-induced apoptosis. These results suggest TAK228 may be an effective new treatment for AT/RT.
引用
- Rubens JA, Wang SZ, Price A, et al. The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity. Neuro Oncol. 2017. PMID: 28582547. doi:10.1093/neuonc/nox067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。